BACKGROUND: Rapidly spreading to new regions, including the islands of the Indian Ocean, Central Africa, and Europe, Chikungunya fever is becoming a major problem of public health. Unlike other members of the alphavirus genus, immune responses to Chikungunya virus (CHIKV) have been poorly investigated. METHODS: We conducted a large ex vivo multiplex study of 50 cytokine, chemokine, and growth factor plasma profiles in 69 acutely infected patients from the Gabonese outbreak of 2007. We also assessed a phenotypic study of T lymphocyte responses during human acute CHIKV infection. RESULTS: CHIKV infection in humans elicited strong innate immunity involving the production of numerous proinflammatory mediators. Interestingly, high levels of Interferon (IFN) α were consistently found. Production of interleukin (IL) 4, IL-10, and IFN-γ suggested the engagement of the adaptive immunity. This was confirmed by flow cytometry of circulating T lymphocytes that showed a CD8+ T lymphocyte response in the early stages of the disease, and a CD4+ T lymphocyte mediated response in the later stages. For the first time to our knowledge, we found evidence of CD95-mediated apoptosis of CD4+ T lymphocytes during the first 2 days after symptoms onset, ex vivo. CONCLUSIONS: Together, our findings suggest that strong innate immunity is required to control CHIKV infection.
BACKGROUND: Rapidly spreading to new regions, including the islands of the Indian Ocean, Central Africa, and Europe, Chikungunya fever is becoming a major problem of public health. Unlike other members of the alphavirus genus, immune responses to Chikungunya virus (CHIKV) have been poorly investigated. METHODS: We conducted a large ex vivo multiplex study of 50 cytokine, chemokine, and growth factor plasma profiles in 69 acutely infectedpatients from the Gabonese outbreak of 2007. We also assessed a phenotypic study of T lymphocyte responses during human acute CHIKV infection. RESULTS:CHIKV infection in humans elicited strong innate immunity involving the production of numerous proinflammatory mediators. Interestingly, high levels of Interferon (IFN) α were consistently found. Production of interleukin (IL) 4, IL-10, and IFN-γ suggested the engagement of the adaptive immunity. This was confirmed by flow cytometry of circulating T lymphocytes that showed a CD8+ T lymphocyte response in the early stages of the disease, and a CD4+ T lymphocyte mediated response in the later stages. For the first time to our knowledge, we found evidence of CD95-mediated apoptosis of CD4+ T lymphocytes during the first 2 days after symptoms onset, ex vivo. CONCLUSIONS: Together, our findings suggest that strong innate immunity is required to control CHIKV infection.
Authors: Nelson Lee; Chun K Wong; Wai Y Lam; Ann Wong; Wilina Lim; Christopher W K Lam; Clive S Cockram; Joseph J Y Sung; Paul K S Chan; Julian W Tang Journal: Emerg Infect Dis Date: 2006-11 Impact factor: 6.883
Authors: Christina L Gardner; Crystal W Burke; Stephen T Higgs; William B Klimstra; Kate D Ryman Journal: Virology Date: 2012-02-01 Impact factor: 3.616
Authors: Haiyan Chu; Subash C Das; Jeremy F Fuchs; M Suresh; Scott C Weaver; Dan T Stinchcomb; Charalambos D Partidos; Jorge E Osorio Journal: Vaccine Date: 2013-05-29 Impact factor: 3.641
Authors: Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban Journal: J Virol Date: 2014-01-08 Impact factor: 5.103
Authors: Emma S Winkler; Swathi Shrihari; Barry L Hykes; Scott A Handley; Prabhakar S Andhey; Yan-Jang S Huang; Amanda Swain; Lindsay Droit; Kranthi K Chebrolu; Matthias Mack; Dana L Vanlandingham; Larissa B Thackray; Marina Cella; Marco Colonna; Maxim N Artyomov; Thaddeus S Stappenbeck; Michael S Diamond Journal: Cell Date: 2020-07-14 Impact factor: 41.582
Authors: Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise Journal: J Virol Date: 2015-10-21 Impact factor: 5.103
Authors: Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb Journal: Expert Rev Vaccines Date: 2012-09 Impact factor: 5.217